Guru P Sonpavde MD

Genitourinary Oncology

GU Oncology & Phase I Clinical Trial Director AdventHealth Cancer Institute Professor, University of Central Florida Orlando, FL, USA

Join to View Full Profile

2501 N Orange AveSte 689Orlando, FL 32804
Phone+1 407-303-2024

Summary

Dr. Guru Sonpavde is an oncologist in Orlando, FL. He received his medical degree from Christian Medical College Vellore and has been in practice 27 years. He specializes in genitourinary oncology and is experienced in Phase I clinical trials and prostate cancer, urologic oncology, bladder cancer, kidney cancer and urinary tract cancer. He has more than ~500 publications.

Current and Emerging Agents to Treat Advanced Bladder Cancer

A New Prognostic Model for Post-Platinum PD-L1 Inhibitors Treatment of Urothelia

A New Prognostic Model for Post-Platinum PD-L1 Inhibitors Treatment of Urothelial Carcinoma

Immunotherapy Outcomes in Pure vs Mixed Urothelial Carcinoma Histology

Education & Training

Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 1995 - 1998
Nassau University Medical CenterResidency, Internal Medicine, 1992 - 1995
Christian Medical College VelloreClass of 1990

Certifications & Licensure

CT State Medical License Current
FL State Medical License 2022 - 2026
MA State Medical License 2017 - 2024
NH State Medical License 2024 - 2024
RI State Medical License 2020 - 2020
AL State Medical License 2012 - 2017
TX State Medical License 2003 - 2013
AZ State Medical License 2001 - 2003
TN State Medical License 1999 - 2002
IN State Medical License 1995 - 1999
American Board of Internal Medicine Medical Oncology
Join now to see all

Clinical Trials

Vidaza to Restore Hormone Thx Prostate Start of enrollment: 2006 Apr 01
Completed
Phase 2
Phase II Sunitinib Prog Met AIPC Start of enrollment: 2007 Mar 01
Completed
Phase 2
Gemzar, Cisp, Sunitinib Urothelial Ca Start of enrollment: 2008 Aug 01
Completed
Phase 2
Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal Start of enrollment: 2011 Apr 01
Terminated
Phase 2
MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer Start of enrollment: 2009 Apr 01
Completed
Phase 1
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
COMPLETED
PHASE1, PHASE2
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma Start of enrollment: 2010 Dec 01
Terminated
Phase 2
A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer Start of enrollment: 2012 Mar 30
TERMINATED
PHASE1, PHASE2
Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 2
Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma Start of enrollment: 2013 Mar 08
Terminated
Phase 1, Phase 2
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
ACTIVE_NOT_RECRUITING
PHASE3
Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 1
Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer Start of enrollment: 2013 Oct 01
Completed
Phase 2
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer Start of enrollment: 2014 Jan 22
Active, not recruiting
Phase 3
Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment Start of enrollment: 2014 Apr 01
Completed
Phase 2
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer Start of enrollment: 2014 May 01
Completed
Phase 2
S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer Start of enrollment: 2014 Aug 28
COMPLETED
PHASE2
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma Start of enrollment: 2015 May 01
Terminated
Phase 1
Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer Start of enrollment: 2015 Aug 27
Completed
Phase 2
Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477) Start of enrollment: 2015 May 01
Completed
Phase 2
Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma Start of enrollment: 2015 Oct 01
Terminated
Phase 2
Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma Start of enrollment: 2016 Oct 01
Terminated
Phase 2
Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma Start of enrollment: 2017 May 23
Withdrawn
Phase 2
Phase I Trial of PACE for Metastatic Prostate Cancer Start of enrollment: 2018 May 09
Withdrawn
Phase 1
A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2) Start of enrollment: 2019 Feb 20
Completed
Phase 1
Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma Start of enrollment: 2021 Jan 21
ACTIVE_NOT_RECRUITING
PHASE2
Sacituzumab Govitecan Plus EV in Metastatic UC Start of enrollment: 2021 May 20
ACTIVE_NOT_RECRUITING
PHASE1
Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients Start of enrollment: 2021 Apr 30
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Join now to see all

Publications & Presentations

PubMed

Cabozantinib plus Pembrolizumab as First-line Therapy for Cisplatin-ineligible Advanced Urothelial Carcinoma: The PemCab Trial.
Rohit K Jain, Umang Swami, Mehmet A Bilen, Georges Gebrael, Kenneth M Boucher
European Urology Oncology. 2025-04-29
A pilot study of [F]F-fluciclovine positron emission tomography/computed tomography for staging muscle invasive bladder cancer preceding radical cystectomy.
Thomas S C Ng, Mofei Liu, Matthew Robertson, Arda Könik, Su Chun Cheng
European Journal of Nuclear Medicine and Molecular Imaging. 2025-04-21
Current update on pharmacological strategies of penile cancer.
Sameer S Deshmukh, Kaustubh S Chaudhari, Arnab Basu, Guru P Sonpavde
Expert Opinion on Pharmacotherapy. 2025-04-15

Journal Articles

Development and Validation of a Prognostic Model for Overall Survival in Chemotherapy-Naïve Men with Metastatic Castration-Resistant Prostate Cancer
G Sonpavde, C S Higano, T M Beer, Annals of Oncology
Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration
Richard S Foster, Lawrence H Einhorn, Christopher J Sweeney, Guru Sonpavde, Costantine Albany, Chandra K Flack, The Journal of Urology
Nomogram to predict the benefit from salvage systemic therapy for advanced urothelial carcinoma.
Sonpavde G, Pond GR, Fougeray R, Bellmunt J., BJU Int, 2014

Lectures

5-factor prognostic model for survival of patients with metastatic urothelial carcinoma receiving three different post-platinum PD-L1 inhibitors.
2019 ASCO Annual Meeting - 6/1/2019
A phase 3 randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO) Â± BMS-986205 in cisplatin-eligible muscle invasive bladder ...
2019 ASCO Annual Meeting - 6/1/2019

Authored Content

PD1/L1 Inhibitor Therapy for Muscle-Invasive Bladder Cancer: Adjuvant or Neoadjuvant + Adjuvant?February 2025
Practice-changing and Practice-impacting Genitourinary Oncology Highlights From the ESMO Congress 2023October 2023
Genitourinary Oncology Highlights From the ASCO Annual Conference 2023June 2023
ASCO GU 2023: Practice Changing, Practice Reaffirming, Practice Informing and Emerging AdvancesFebruary 2023
GU Updates Abound at ASCO 2021June 2021
Cancer treatment: is a clinical trial right for youMarch 2019
Immunotherapy for cancer therapy: What you need to knowJanuary 2019
Join now to see all

Press Mentions

Innovative Spring Sees Three Groundbreaking Cardiovascular Procedures Performed by AdventHealth PhysiciansJune 4th, 2024
Groundbreaking Ozempic Study – Conducted in Part at AdventHealth – Could Increase Access for People with Chronic Kidney DiseaseMay 29th, 2024
New Approaches in the Bladder-Sparing ParadigmMarch 20th, 2023
Join now to see all